NO20084963L - Krystallinske former av (trans-4-[({5-[3,4-difluorofenyl)amino]-1,3,4-oksadiazol-2-yl}karbonyl)amino]fenyl}cykloheksyl)eddiksyre - Google Patents

Krystallinske former av (trans-4-[({5-[3,4-difluorofenyl)amino]-1,3,4-oksadiazol-2-yl}karbonyl)amino]fenyl}cykloheksyl)eddiksyre

Info

Publication number
NO20084963L
NO20084963L NO20084963A NO20084963A NO20084963L NO 20084963 L NO20084963 L NO 20084963L NO 20084963 A NO20084963 A NO 20084963A NO 20084963 A NO20084963 A NO 20084963A NO 20084963 L NO20084963 L NO 20084963L
Authority
NO
Norway
Prior art keywords
amino
oxadiazol
difluorophenyl
cyclohexyl
trans
Prior art date
Application number
NO20084963A
Other languages
English (en)
Inventor
Andrew Hornby Dobson
Walter Grundy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084963L publication Critical patent/NO20084963L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
NO20084963A 2006-06-12 2008-11-26 Krystallinske former av (trans-4-[({5-[3,4-difluorofenyl)amino]-1,3,4-oksadiazol-2-yl}karbonyl)amino]fenyl}cykloheksyl)eddiksyre NO20084963L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds
PCT/GB2007/002097 WO2007144571A1 (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid

Publications (1)

Publication Number Publication Date
NO20084963L true NO20084963L (no) 2009-01-07

Family

ID=36745696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084963A NO20084963L (no) 2006-06-12 2008-11-26 Krystallinske former av (trans-4-[({5-[3,4-difluorofenyl)amino]-1,3,4-oksadiazol-2-yl}karbonyl)amino]fenyl}cykloheksyl)eddiksyre

Country Status (16)

Country Link
EP (1) EP2041101A1 (no)
JP (1) JP2009539954A (no)
KR (1) KR20090015980A (no)
CN (1) CN101466690A (no)
AR (1) AR061332A1 (no)
AU (1) AU2007259031A1 (no)
BR (1) BRPI0712354A2 (no)
CA (1) CA2653550A1 (no)
CL (1) CL2007001700A1 (no)
GB (1) GB0611552D0 (no)
IL (1) IL195348A0 (no)
MX (1) MX2008015762A (no)
NO (1) NO20084963L (no)
TW (1) TW200815378A (no)
UY (1) UY30404A1 (no)
WO (1) WO2007144571A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555683A (en) 2004-12-14 2010-09-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
PL2402319T3 (pl) 2006-03-31 2018-02-28 Novartis Ag Inhibitory DGAT
WO2007138304A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
ES2356097T3 (es) 2006-05-30 2011-04-04 Astrazeneca Ab Ácidos 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-ciclohexancarboxílico sustituidos como inhibidores de la acetil coenzima a diacilglicerol aciltransferasa.
WO2008099221A1 (en) * 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
ES2535083T3 (es) 2007-12-20 2015-05-05 Astrazeneca Ab Compuestos de carbamoilo como inhibidores 190 de DGAT1
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
WO2010146395A1 (en) 2009-06-19 2010-12-23 Astrazeneca Ab Pyrazine carboxamides as inhibitors of dgat1
FR2963005B1 (fr) * 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
NZ555683A (en) * 2004-12-14 2010-09-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors

Also Published As

Publication number Publication date
WO2007144571A1 (en) 2007-12-21
KR20090015980A (ko) 2009-02-12
BRPI0712354A2 (pt) 2012-06-05
UY30404A1 (es) 2008-01-31
TW200815378A (en) 2008-04-01
GB0611552D0 (en) 2006-07-19
CN101466690A (zh) 2009-06-24
AR061332A1 (es) 2008-08-20
CA2653550A1 (en) 2007-12-21
MX2008015762A (es) 2009-03-16
JP2009539954A (ja) 2009-11-19
AU2007259031A1 (en) 2007-12-21
IL195348A0 (en) 2009-08-03
CL2007001700A1 (es) 2008-01-18
EP2041101A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
NO20084963L (no) Krystallinske former av (trans-4-[({5-[3,4-difluorofenyl)amino]-1,3,4-oksadiazol-2-yl}karbonyl)amino]fenyl}cykloheksyl)eddiksyre
IL195882A (en) Crystalline forms of derivatives of (1 s) –1, 5 – anhydro – 1– c - (3 - ((phenyl) methyl) phenyl) - d -glucitol with amino acids and their use in the treatment of diabetes
ZA200705834B (en) Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
HK1183875A1 (zh) -氯- 三氟甲基 苯基 -二氫- 三氟甲基 -異噁唑基 -氧代- -三氟乙基 氨基 乙基 -萘甲酰胺的晶形
DE602007011843D1 (de) Verfahren zur Herstellung von Gruppe-III-Nitridkristallen
SI2097381T1 (sl) 4-(4-((4-kloro-3-(trifluorometil)fenil))karbamoil)amino)-3- fluorofenoksi)-n-metilpiridin-2-karbokasamid monohidrat
BRPI0914959A2 (pt) sais recentes de ácido (4{[(5-{[(3-clorofenil)metil]oxi}-2-metilfenil)carbonila]amino}-3-metilfenil)acético
RS52988B (en) Trans-4 - [[(5S) -5 - [[[3,5-bis (trifluoromethyl) phenyl] methyl] (2-methyl-2H-tetrazol-5-yl) amino] -2,3,4,5 -TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-yl] METHYL] -CYCLOHEXANECARBOXYLIC ACID
FR2933454B1 (fr) Module d'injection pour soupape d'injection
BRPI0716127A2 (pt) moldagem por injeÇço de elementos cerÂmicos
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ITTO20060716A1 (it) Iniettore per stampaggio ad iniezione di materie plastiche
ZA200807190B (en) Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
IL219282A0 (en) Process for production of 3 - [5 - [4 - (cyclopentyloxy) - 2 - hydroxybenzoyl] - 2 - [(3 - oxo - 2 - substituted - 2, 3 - dihydro - 1, 2- benzisoxazol - 6 - yl) methoxy]phenyl] propionate ester and intermediate for the process
ITTO20060063A1 (it) Corredo per l'amplificazione di acidi nucleici.
BRPI0816140A2 (pt) Modificação cristalina termodinamicamente estável de 2-({2-cloro-4-(metilsulfonil)-3-{(2,2,2-trifluoretóxi)me til]fenil}carbonil)ciclo-hexan-1,3-diona.
CL2007001691A1 (es) Metodo para hacer n-hidroxi-3-(4(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida.
DK2435406T3 (da) Opløsning af (±)-METHYL PHENYL[4-[4-[[[4'-(TRIFLUOROMETHYL)-2-BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETAT
ATE545106T1 (de) Spritzguss-formkörper
AU2006201692A1 (en) Modifying the weld line of an injection moulding
NO20055481D0 (no) Fremgangsmate for gjenfangst av romt oppdrettsfisk
TH91734B (th) โคมไฟ
HN2008001862A (es) Polimorfos de n-hodroxi-3 [4-[[[2-metil-1h-indol-3-il)etil]amino] metil]fenil]-2e-2-2propenamida